Hangzhou Kangwanda Pharmaceutical Technology

Hangzhou Kangwanda Pharmaceutical Technology is a clinical-stage biotechnology company focused on the development of innovative oncolytic virus (OV) therapies for cancer treatment. The company was founded by Dr. Hu Fang, who led the development of the world's first approved oncolytic virus drug, Oncorine. Kangwanda leverages its proprietary Kandle platform to develop next-generation OVs capable of systemic administration, addressing the limitations of local intratumoral injection. Their pipeline targets a variety of solid tumors, including liver and pancreatic cancers, by combining viral oncolysis with immune-stimulating payloads. The company is headquartered in Hangzhou, China, where it maintains integrated R&D and pilot manufacturing facilities. Kangwanda has secured significant venture capital funding to advance its lead candidates through clinical trials.